171 related articles for article (PubMed ID: 37587486)
21. Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
Endo S; Xia S; Suyama M; Morikawa Y; Oguri H; Hu D; Ao Y; Takahara S; Horino Y; Hayakawa Y; Watanabe Y; Gouda H; Hara A; Kuwata K; Toyooka N; Matsunaga T; Ikari A
J Med Chem; 2017 Oct; 60(20):8441-8455. PubMed ID: 28976752
[TBL] [Abstract][Full Text] [Related]
22. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
[TBL] [Abstract][Full Text] [Related]
23. [Aldo-keto reductase family 1 B10 participates in the regulation of hepatoma cell cycle through p27/p-Rb signaling pathway].
Geng N; Jin YY; Zhu SX; Li YR; Zheng LY; Zhu WJ; Li YW; Han C; Dou XG; Bai H
Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):861-867. PubMed ID: 33105932
[No Abstract] [Full Text] [Related]
24. Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.
Nagai H; Yasuda H; Hatachi Y; Xue D; Sasaki T; Yamaya M; Sakamori Y; Togashi Y; Masago K; Ito I; Kim YH; Mio T; Mishima M
Int J Oncol; 2012 Jul; 41(1):24-30. PubMed ID: 22552400
[TBL] [Abstract][Full Text] [Related]
25. Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Loeffler-Ragg J; Mueller D; Gamerith G; Auer T; Skvortsov S; Sarg B; Skvortsova I; Schmitz KJ; Martin HJ; Krugmann J; Alakus H; Maser E; Menzel J; Hilbe W; Lindner H; Schmid KW; Zwierzina H
Mol Cancer Ther; 2009 Jul; 8(7):1995-2006. PubMed ID: 19567817
[TBL] [Abstract][Full Text] [Related]
26. Nitric oxide confers cisplatin resistance in human lung cancer cells through upregulation of aldo-keto reductase 1B10 and proteasome.
Matsunaga T; Yamaji Y; Tomokuni T; Morita H; Morikawa Y; Suzuki A; Yonezawa A; Endo S; Ikari A; Iguchi K; El-Kabbani O; Tajima K; Hara A
Free Radic Res; 2014 Nov; 48(11):1371-85. PubMed ID: 25156503
[TBL] [Abstract][Full Text] [Related]
27. Aplastic anemia in a lung adenocarcinoma patient receiving pemetrexed.
Matama G; Tokito T; Takeoka H; Hiraoka Y; Matsuo N; Nakamura M; Ishii H; Kinoshita T; Azuma K; Yamada K; Hoshino T
Invest New Drugs; 2017 Oct; 35(5):662-664. PubMed ID: 28361276
[TBL] [Abstract][Full Text] [Related]
28. AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
Zhong L; Shen H; Huang C; Jing H; Cao D
Toxicol Appl Pharmacol; 2011 Aug; 255(1):40-7. PubMed ID: 21640744
[TBL] [Abstract][Full Text] [Related]
29. High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase.
Kuo WT; Tu DG; Chiu LY; Sheu GT; Wu MF
Oncol Rep; 2017 Nov; 38(5):2787-2795. PubMed ID: 28901493
[TBL] [Abstract][Full Text] [Related]
30. Homeobox A5 activates p53 pathway to inhibit proliferation and promote apoptosis of adrenocortical carcinoma cells by inducing Aldo-Keto reductase family 1 member B10 expression.
Chen D; Shen Z; Cheng X; Wang Q; Zhou J; Ren F; Sun Y; Wang H; Huang R
Bioengineered; 2021 Dec; 12(1):1964-1975. PubMed ID: 34027794
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).
Fukuda M; Kitazaki T; Ogawara D; Ichiki M; Mukae H; Maruyama R; Nakagaki N; Shimada M; Ikeda T; Kishimoto J; Harada T; Seto T; Ebi N; Takayama K; Okamoto I; Ichinose Y; Sugio K
Lung Cancer; 2019 Jun; 132():1-8. PubMed ID: 31097081
[TBL] [Abstract][Full Text] [Related]
32. AKR1B10 inhibits the proliferation and migration of gastric cancer via regulating epithelial-mesenchymal transition.
Shao X; Wu J; Yu S; Zhou Y; Zhou C
Aging (Albany NY); 2021 Sep; 13(18):22298-22314. PubMed ID: 34552036
[TBL] [Abstract][Full Text] [Related]
33. Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective study.
Zhu W; Røe OD; Wu C; Li W; Guo R; Gu Y; Liu Y; Shu Y; Chen X
J Chemother; 2015 Aug; 27(4):221-6. PubMed ID: 25735792
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W
J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297
[TBL] [Abstract][Full Text] [Related]
35. Lung cancer specific and reduction-responsive chimaeric polymersomes for highly efficient loading of pemetrexed and targeted suppression of lung tumor in vivo.
Yang W; Yang L; Xia Y; Cheng L; Zhang J; Meng F; Yuan J; Zhong Z
Acta Biomater; 2018 Apr; 70():177-185. PubMed ID: 29410335
[TBL] [Abstract][Full Text] [Related]
36. Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10.
Morikawa Y; Kezuka C; Endo S; Ikari A; Soda M; Yamamura K; Toyooka N; El-Kabbani O; Hara A; Matsunaga T
Chem Biol Interact; 2015 Mar; 230():30-9. PubMed ID: 25686905
[TBL] [Abstract][Full Text] [Related]
37. Proteomic Reveals Reasons for Acquired Drug Resistance in Lung Cancer Derived Brain Metastasis Based on a Newly Established Multi-Organ Microfluidic Chip Model.
Xu M; Wang Y; Duan W; Xia S; Wei S; Liu W; Wang Q
Front Bioeng Biotechnol; 2020; 8():612091. PubMed ID: 33415100
[TBL] [Abstract][Full Text] [Related]
38. Structure and promoter characterization of aldo-keto reductase family 1 B10 gene.
Liu Z; Zhong L; Krishack PA; Robbins S; Cao JX; Zhao Y; Chung S; Cao D
Gene; 2009 May; 437(1-2):39-44. PubMed ID: 19236911
[TBL] [Abstract][Full Text] [Related]
39. Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Chung YT; Matkowskyj KA; Li H; Bai H; Zhang W; Tsao MS; Liao J; Yang GY
Mod Pathol; 2012 May; 25(5):758-66. PubMed ID: 22222635
[TBL] [Abstract][Full Text] [Related]
40. Loss of AKR1B10 promotes colorectal cancer cells proliferation and migration via regulating FGF1-dependent pathway.
Yao Y; Wang X; Zhou D; Li H; Qian H; Zhang J; Jiang L; Wang B; Lin Q; Zhu X
Aging (Albany NY); 2020 Jul; 12(13):13059-13075. PubMed ID: 32615540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
